File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)

Conference Paper: A randomised clinical trial comparing thesublingual and buccal routes of administration ofmisoprostol after mifepristone for medicaltermination of pregnancy of up to 63 days ofgestation

TitleA randomised clinical trial comparing thesublingual and buccal routes of administration ofmisoprostol after mifepristone for medicaltermination of pregnancy of up to 63 days ofgestation
Authors
Issue Date2012
PublisherWiley-Blackwell Publishing Ltd.. The Journal's web site is located at http://www.bjog.org/
Citation
The RCOG 10th International Scientific Congress, Kuching, Sarawak, Malaysia, 5-8 June 2012. In BJOG, 2012, v. 119 suppl. s1, p. 139 How to Cite?
AbstractObjective: Buccal misoprostol 800 mcg and sublingual 800 mcgshow high efficacy when used with 200 mg mifepristone for earlypregnancy termination but with different profiles of side effects.This is the first double-blind randomized trial comparing thesetwo routes for termination of early pregnancies up to 63 daysgestation.Methods: Eligible women (n = 90) who requested legaltermination of pregnancy up to 63 days gestation wererandomized to two groups and given 200 mg of oral mifepristonefollowed 48 h later by either 800 mcg of sublingual (n = 45) orbuccal (n = 45) misoprostol.Results: Similar proportion of women experienced fever insublingual and buccal groups (37.8% vs. 22.2%, P = 0.107). Theincidence of chills was significantly higher in the sublingual group(55.6% vs. 91.1%, P = 0.0001). Complete termination ofpregnancy occurred in 95.4% (95% CI: 84.9–99.5) of women inthe buccal group and 97.8% (95% CI: 88.2–99.9) in the sublingualgroup. Conclusions: When combined with mifepristone for terminationof pregnancy up to 63 days, sublingual administration ofmisoprostol is associated with more chills but not other sideeffects when compared with buccal administration.
Persistent Identifierhttp://hdl.handle.net/10722/153218
ISSN
2015 Impact Factor: 4.039
2015 SCImago Journal Rankings: 2.083

 

DC FieldValueLanguage
dc.contributor.authorChai, J-
dc.contributor.authorHo, PC-
dc.date.accessioned2012-07-16T10:00:21Z-
dc.date.available2012-07-16T10:00:21Z-
dc.date.issued2012-
dc.identifier.citationThe RCOG 10th International Scientific Congress, Kuching, Sarawak, Malaysia, 5-8 June 2012. In BJOG, 2012, v. 119 suppl. s1, p. 139-
dc.identifier.issn1470-0328-
dc.identifier.urihttp://hdl.handle.net/10722/153218-
dc.description.abstractObjective: Buccal misoprostol 800 mcg and sublingual 800 mcgshow high efficacy when used with 200 mg mifepristone for earlypregnancy termination but with different profiles of side effects.This is the first double-blind randomized trial comparing thesetwo routes for termination of early pregnancies up to 63 daysgestation.Methods: Eligible women (n = 90) who requested legaltermination of pregnancy up to 63 days gestation wererandomized to two groups and given 200 mg of oral mifepristonefollowed 48 h later by either 800 mcg of sublingual (n = 45) orbuccal (n = 45) misoprostol.Results: Similar proportion of women experienced fever insublingual and buccal groups (37.8% vs. 22.2%, P = 0.107). Theincidence of chills was significantly higher in the sublingual group(55.6% vs. 91.1%, P = 0.0001). Complete termination ofpregnancy occurred in 95.4% (95% CI: 84.9–99.5) of women inthe buccal group and 97.8% (95% CI: 88.2–99.9) in the sublingualgroup. Conclusions: When combined with mifepristone for terminationof pregnancy up to 63 days, sublingual administration ofmisoprostol is associated with more chills but not other sideeffects when compared with buccal administration.-
dc.languageeng-
dc.publisherWiley-Blackwell Publishing Ltd.. The Journal's web site is located at http://www.bjog.org/-
dc.relation.ispartofBJOG: an international journal of obstetrics and gynaecology-
dc.rightsPreprint This is the pre-peer reviewed version of the following article: [FULL CITE], which has been published in final form at [Link to final article]. Authors are not required to remove preprints posted prior to acceptance of the submitted version. Postprint This is the accepted version of the following article: [full citation], which has been published in final form at [Link to final article].-
dc.titleA randomised clinical trial comparing thesublingual and buccal routes of administration ofmisoprostol after mifepristone for medicaltermination of pregnancy of up to 63 days ofgestation-
dc.typeConference_Paper-
dc.identifier.emailChai, J: jchai@hkucc.hku.hk-
dc.identifier.emailHo, PC: pcho@hku.hk-
dc.identifier.authorityChai, J=rp00241-
dc.identifier.authorityHo, PC=rp00325-
dc.identifier.doi10.1111/j.1471-0528.2012.03378.x-
dc.identifier.hkuros200623-
dc.identifier.volume119-
dc.identifier.issuesuppl. s1-
dc.identifier.spage139-
dc.identifier.epage139-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats